Investors can certainly boost their returns by concentrating on stocks trading between $1 and $10. However, a disciplined approach is necessary because many of these businesses are speculative and lack the underlying fundamentals to support their prices.
The bad behavior exhibited by lower-quality companies in this space can spook even the most seasoned professionals, which is why we started StockStory - to separate the good from the bad. Keeping that in mind, here are three stocks under $10 to swipe left on and some alternatives you should look into instead.
Angi (ANGI)
Share Price: $8.84
Created by IAC’s mergers of Angie’s List and HomeAdvisor, ANGI (NASDAQ: ANGI) operates the largest online marketplace for home services in the US.
Why Does ANGI Give Us Pause?
- Service Requests have declined by 21.3% annually over the last two years, suggesting it may need to revamp its features or user experience to stay competitive
- Projected sales growth of 1.1% for the next 12 months suggests sluggish demand
- Highly competitive market means it’s on the never-ending treadmill of sales and marketing spend
Angi’s stock price of $8.84 implies a valuation ratio of 3.9x forward EV/EBITDA. To fully understand why you should be careful with ANGI, check out our full research report (it’s free).
AerSale (ASLE)
Share Price: $6.45
Providing a one-stop shop that integrates multiple services and product offerings, AerSale (NASDAQ: ASLE) delivers full-service support to mid-life commercial aircraft.
Why Do We Pass on ASLE?
- Products and services are facing end-market challenges during this cycle, as seen in its flat sales over the last two years
- Free cash flow margin dropped by 31.4 percentage points over the last five years, implying the company became more capital intensive as competition picked up
- Shrinking returns on capital from an already weak position reveal that neither previous nor ongoing investments are yielding the desired results
At $6.45 per share, AerSale trades at 9.6x forward P/E. If you’re considering ASLE for your portfolio, see our FREE research report to learn more.
Myriad Genetics (MYGN)
Share Price: $4.99
Founded in 1991 as one of the pioneers in translating genetic discoveries into clinical applications, Myriad Genetics (NASDAQ: MYGN) develops genetic tests that assess disease risk, guide treatment decisions, and provide insights across oncology, women's health, and mental health.
Why Is MYGN Risky?
- Sales trends were unexciting over the last two years as its 4.6% annual growth was below the typical healthcare company
- Push for growth has led to negative returns on capital, signaling value destruction, and its falling returns suggest its earlier profit pools are drying up
- Shrinking returns on capital from an already weak position reveal that neither previous nor ongoing investments are yielding the desired results
Myriad Genetics is trading at $4.99 per share, or 75.7x forward P/E. Read our free research report to see why you should think twice about including MYGN in your portfolio.
Stocks We Like More
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don't just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn't over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
